Establishment Labs (NASDAQ:ESTA - Free Report) had its price objective upped by Citigroup from $38.00 to $47.00 in a report issued on Wednesday morning,Benzinga reports. They currently have a neutral rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Establishment Labs from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. Needham & Company LLC reissued a "buy" rating and issued a $48.00 price target on shares of Establishment Labs in a research report on Friday, June 13th. Finally, BTIG Research began coverage on shares of Establishment Labs in a research report on Friday, May 16th. They issued a "buy" rating and a $62.00 price target for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $51.80.
Get Our Latest Report on ESTA
Establishment Labs Stock Up 3.7%
Shares of NASDAQ:ESTA traded up $1.67 during trading on Wednesday, hitting $46.73. The company's stock had a trading volume of 8,478 shares, compared to its average volume of 476,492. The business has a 50 day moving average price of $37.68 and a two-hundred day moving average price of $36.94. The company has a market capitalization of $1.35 billion, a PE ratio of -15.07 and a beta of 0.80. The company has a debt-to-equity ratio of 5.72, a quick ratio of 2.05 and a current ratio of 3.36. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $52.41.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.13. The business had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The company's quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.58) earnings per share. As a group, research analysts expect that Establishment Labs will post -2.41 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in ESTA. Toronto Dominion Bank acquired a new position in shares of Establishment Labs during the fourth quarter worth about $24,879,000. Brown Advisory Inc. increased its stake in shares of Establishment Labs by 23.1% during the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock worth $107,729,000 after acquiring an additional 438,057 shares during the period. Capital Research Global Investors increased its stake in shares of Establishment Labs by 29.3% during the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after acquiring an additional 433,484 shares during the period. Voya Investment Management LLC increased its stake in shares of Establishment Labs by 7,249.5% during the fourth quarter. Voya Investment Management LLC now owns 408,262 shares of the company's stock worth $18,809,000 after acquiring an additional 402,707 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Establishment Labs by 96.9% during the fourth quarter. Millennium Management LLC now owns 711,691 shares of the company's stock worth $32,788,000 after acquiring an additional 350,213 shares during the period. 72.91% of the stock is currently owned by institutional investors and hedge funds.
Establishment Labs Company Profile
(
Get Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Recommended Stories

Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.